Stacey J. Adam, Ph.D., Stanford University, Stanford, CA, Abstract #4879
Distinct roles of p53 and p19ARF in MYC-dependent tumor oncogene addiction
Anna M. Azarova, Ph.D., Dana-Farber Cancer Institute, Boston, MA, Abstract #2935
The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma
Paloma Bragado, Ph.D., Mount Sinai School of Medicine, New York, NY, Abstract #5234
Microenvironmental signals dictate disseminated tumor cells (DTCs) fate through regulation of TGFβII and p38α
Andrea N. Burnett-Hartman, Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA, Abstract #1673
BRAF mutation is associated with large, proximal sessile serrated polyps, but not with adenomas
Zafira Castano, Ph.D., Brigham Women's Hospital, Harvard Medical School, Boston, MA, Abstract #4861
Triple-negative breast cancers establish a systemic environment that drives malignant progression of otherwise indolent disseminated tumors via EGF and IGF
Katherine L. Cook, Ph.D., Georgetown University, Washington, DC, Abstract #4995
Glucose-regulated protein 78 regulates crosstalk between apoptosis and autophagy to determine antiestrogen responsiveness
Catherine A. Del Vecchio, B.A., Stanford University, Stanford, CA, Abstract #10
Oncogenic variant EGFRvIII defines a hierarchy in glioblastoma and expression is restricted by epigenetic mechanisms despite the presence of gene amplification
Lissette Delgado-Cruzata, Ph.D., Columbia University School of Public Health, New York, NY, Abstract #4482
Effects of lifestyle modification on global DNA methylation in minority breast cancer survivors
Emily M. Fox, Ph.D., Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, TN, Abstract #4825
Inhibition of AKT abrogates resistance to endocrine therapy in estrogen receptor positive breast cancer
Joan T. Garrett, Ph.D., Vanderbilt University, Nashville, TN, Abstract #3867
Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications
Xiaolan Guo, M.D., Ph.D., University of Minnesota Hormel Institute, Austin, MN, Abstract #1173
AKT-mTOR pathway mediates mutant p53 gain-of-function by inhibiting autophagy
Karin G. Hermans, Ph.D., University Health Network, Toronto, Ontario, Abstract #3330
Functional characterization of microRNAs identified in human acute myeloid leukemia stem cells
Christine How, B.S., University of Toronto, Toronto, Ontario, Abstract #2311
microRNA-196b regulates HOXB7 in cervical cancer
Andrea L. Kasinski, Ph.D., Yale University, New Haven, CT, Abstract #2950
miR-34 prevents in vivo lung tumor initiation and progression in the therapeutically resistant Kras; p53 mouse model
Kate Lawrenson, Ph.D., University of Southern California, Los Angeles, CA, Abstract #2928
Functional Effects of SNPs in Non-coding RNAs at the 3q25 Ovarian Cancer Susceptibility Locus
Vivian S.W. Li, Ph.D., Hubrecht Institute, Utrecht, The Netherlands, Abstract #983
Wnt pathway activation involves inhibition of β-catenin ubiquitination within the endogenous Axin1 complex
Monica Mann, B.S., UTHSCSA, San Antonio, TX, Abstract #5628
Novel cell permeable peptide inhibitors of PELP1 oncogenic functions.
Tapati Mazumdar, Ph.D., The Cleveland Clinic, Cleveland, OH, Abstract #898
Hedgehog signaling (HH/Gli) transcriptionally regulates hTERT gene expression in human cancer cells
Ying Ni, M.S., The Cleveland Clinic, Cleveland, OH, Abstract #1120
α-Tocopherol protects cells from lipid peroxidation and rescues tumorigenic phenotypes in CS/CSL patients with germline SDHx variants
Mukti Parikh, M.S., Purdue University, West Lafayette, IN, Abstract #3306
A novel reconstructed metastasis (rMet) model to understand the role of breast cancer stem cells in metastasis
Ruth Perets, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA, Abstract #3292
A genetically engineered mouse model for high grade serous “ovarian” carcinoma arising in the fallopian tube
Aparna Rao, M.S., University of Pittsburgh, Pittsburgh, PA, Abstract #4399
Immunostimulatory effects of HSP90 inhibition: Insights from combinational immunotherapies targeting EphA2
Jaya Sangodkar, B.S., Mount Sinai School of Medicine, New York, NY, Abstract #1885
Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy
Raphaela Schwentner, M.Sc., Children's Cancer Research Institute, Vienna, Austria, Abstract #2198
A functional ETS/E2F module in cancers expressing ETS fusion genes
Bing Song, Ph.D., Purdue University, West Lafayette, IN, Abstract #2050
Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress
Maria S. Sosa, Ph.D., Mount Sinai School of Medicine, New York, NY, Abstract #4262
NR2F1 and SOX9 mediate reprogramming of tumor cells into dormancy. Potential role in dormant bone marrow DTCs
Christina Vorvis, B.S., Dana-Farber Cancer Institute, Boston, MA, Abstract #5335
Identification and Molecular Characterization of Pancreatic Tumor-Initiating Cells
Sarah R. Walker, Ph.D., Dana-Farber Cancer Institute, Boston, MA, Abstract #971
Identification of BCL6 targeted therapies for breast cancer through gene expression networks
Xiaoqi Xie, Ph.D., The Cancer Institute of New Jersey/UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, Abstract #2276
Coordinate Autophagy and PI3K/Akt/mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Pan Zhang, M.D., Ph.D., UMDNJ-New Jersey Medical School, Newark, NJ, Abstract #2121
Nonerythroid alpha spectrin prevents telomere fragility after DNA interstrand crosslink damage